H Pylori Infection Clinical Trial
Official title:
Helicobacter Pylori and it's Hematological Impact
To evaluate the effect of helicobacter pylori on the blood for proper management
r pylori (H. pylori)is the most common infection in humans, with a marked disparity between
developed and developing countries.It presents in over 50% of all stomachs in the world
population, making it the most frequent infection in humanS. It displays a marked disparity
in occurrence between developed countries, where its prevalence oscillates between 30% and
50%, and developing countries, where its prevalence ranges between 80% and 90%.
Although H. pylori infections are asymptomatic in most infected individuals, they are
intimately related to malignant gastric conditions such as gastric cancer and gastric
mucosa-associated lymphoid tissue (MALT) lymphoma and to benign diseases such as gastritis
and duodenal and gastric peptic ulcers.
Since it was learned that bacteria could colonize the gastric mucosa, there have been reports
in the medical literature of over 50 extragastric manifestations involving a variety medical
areas of specialization. These areas include cardiology, dermatology, endocrinology,
gynecology and obstetrics, hematology, pneumology, odontology, ophthalmology,
otorhinolaryngology and pediatrics, and they encompass conditions with a range of clear
evidence between the H. pylori infection and development of the disease.
This review focuses on hematologic diseases included in international consensus and
management guides for H. pylori infection; specifically iron deficiency Anemia, vitamin B12
(cobalamin) deficiency, immune thrombocytopenia, and extranodal marginal zone
mucosa-associated lymphoid tissue lymphoma (MALT Lymphoma). In addition of other hematologic
diseases not included in guides and consensus as auto-immune neutropenia, antiphospholipid
syndrome, and plasma cell dyscrasias.
Iron deficiency Iron deficiency (ID) is a serious public health issue, regardless of whether
it is associated with anemia . It is especially important to remember that ID is a chronic
process with a slow onset, in which the iron imbalance may take several years to establish
and manifest clinically. One of the consequences can be observed through blood
characteristics such as morphological alterations of erythrocytes or the presence of anemia,
according to the criteria of the WHO.ID occurs in three stages: pre-latent (stage 1), in
which ferritin is between 12 and 30 μg/L, latent (stage 2) when the ferritin falls below 12
μg/L, and ID anemia (stage 3) when anemia is present in addition to diminished or depleted
reservoir iron levels (determined by serum ferritin).
Vitamin B12 deficiency Vitamin B12 is required as a coenzyme for the metabolism of the amino
acids methionine, threonine and valine and for the transformation of methyl-tetrahydrofolate
to tetrahydrofolate, which is necessary for DNA synthesis. Vitamin B12 deficiency, also known
as cobalamin deficiency, is defined by low serum values of vitamin B12 and both homocysteine
and methylmalonic acid (two components of the vitamin B12 metabolic pathway). Vitamin B12
deficiency occurs as a result of antibodies directed against gastric parietal cells and
intrinsic factor, in addition to achlorhydria and a decrease in pepsinogen I and gastrin.
The laboratory diagnosis of vitamin B12 deficiency is established in accordance with the
following criteria:
1. serum vitamin B12 levels < 150 pmol/L (< 200 pg/mL) with clinical features and/or
hematological anomalies related to vitamin B12 deficiency
2. serum vitamin B12 levels < 150 pmol/L on two separate occasions .
3. serum vitamin B12 levels < 150 pmol/L and total serum homocysteine levels > 13 μmol/L or
methylmalonic acid levels > 0.4 μmol/L (in the absence of renal failure and folate and
vitamin B6 deficiencies).
4. serum holotranscobalamin levels < 35 pmol/L. Immune thrombocytopenia Primary immune
thrombocytopenia (ITP), previously called idiopathic thrombocytopenic purpura and
autoimmune thrombocytopenic purpura.ITP has been redefined as "an autoimmune disorder
characterized by isolated thrombocytopenia (peripheral blood platelet count 100 × 109/L)
in the absence of other causes or disorders that may be associated with
thrombocytopenia.
Primary ITP is associated with congenital or acquired immune disorders, leading to an
autoimmune response against platelets or megakaryocytes and characterized because it is not
associated with other alterations.
Gastric MALT lymphoma Gastric MALT lymphoma is a rare form of non-Hodgkin lymphoma that
affects B lymphocytes and typically develops in lymphoid tissue associated with mucous
membranes and rarely in lymph nodes. It represents approximately 5% of all diagnosed
non-Hodgkin lymphomas.
The mechanisms by which H. pylori produces the appearance of a lymphoma similar to gastric
carcinogenesis has not been fully clarified, but it is likely that environmental, host, and
bacterial-related factors must be involved.H. pylori infection leads to development of MALT
lymphoma and can take the following course. First, the infection gives rise to a lymphocyte
response that conditions a polyclonal B lymphocyte response and MALT formation through
antibody production. Then, different lymphocyte populations would maintain the response
provoked by the bacteria. In the polyclonal MALT proliferation, a monoclonal population of
B-cells could appear and accumulate cytogenetic changes such as translocations, mutations,
microsatellite instabilities, eventually evolving into a low-grade MALT lymphoma that is
dependent on H. pylori-related antigen stimuli. Finally, new cytogenetic changes such as
translocations, suppressor gene deactivation (p53 and p16, among others), and c-myc
activation would make this neoplastic population of monoclonal B-cells escape from its
dependence on T lymphocytes and H. pylori antigens and favor its transformation into a
high-grade lymphoma. As a result of this sequence of events, a low- or high-grade lymphoma
would ultimately develop.
UNRECOGNIZED HEMATOLOGIC MANIFESTATIONS This group includes autoimmune neutropenia,
antiphospholipid syndrome, plasma cell dyscrasia including monoclonal gammopathy of
undetermined significance and multiple myeloma.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05444439 -
Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy
|
N/A | |
Recruiting |
NCT03347513 -
Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy?
|
Phase 4 | |
Completed |
NCT05680532 -
The Improvement of Black Raspberry in Obese and Mild AZ Patients Infected With H. Pylori
|
N/A | |
Recruiting |
NCT06275204 -
H. Pylori Screen-and-treat Study in a Population of Young Adults
|
||
Completed |
NCT03857425 -
Helicobacter Pylori Eradication With Clostridum Butyricum Capsule and Bacillus Coagulans Tablets
|
Phase 4 | |
Recruiting |
NCT03555526 -
Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection
|
Phase 4 | |
Not yet recruiting |
NCT05789550 -
HELICOBACTER PYLORI INFECTION IN TYPE 2 DIABETES MELLITUS IN ASSIUT UNIVERSITY HOSPITAL
|
||
Not yet recruiting |
NCT03911791 -
Screening of Helicobacter Pylori in Children of Positive Infected Mothers
|